Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Q4 Pharma Earnings Preview: GSK, Lilly, Sanofi And AstraZeneca

Executive Summary

GlaxoSmithKline will update investors on strategy after completing its Tesaro acquisition. Lilly may have guidance updates following its Loxo acquisition and Lartruvo setback news. Sanofi investors await a pair of new approvals, and AstraZeneca faces investors for the first time since the departure of Chief Medical Officer Sean Bohen and establishing a new organizational structure.

Advertisement

Related Content

Generic Advair: Finally Approved, A Long Time Coming
Lartruvo Phase III Fail Rocks Lilly Oncology Plans
Sanofi's Sotagliflozin: Risk Of Ketoacidosis Divides US FDA Advisory Committee
Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron
Lift-Off For Lilly In Cancer Genetics With Loxo Buy
MyoKardia Frames End Of Sanofi Partnership As A Bet On Itself
First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza
GSK Embraces PARP Promise With Tesaro Buy
Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase
PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel